In summary, we found that IFITM3 could serve as a potent biomarker for predicting immunotherapy efficacy in SCLC and that its overexpression could enhance CD8+ T-cell infiltration and promote antitumor immunity. This evidence concerns the gene CD8A and small cell lung carcinoma.